Question of the Day

Question of the Day – Monday July 24, 2017

Question:  Occupational exposure to the chemical carbon disulfide has been associated with a wide variety of adverse health effects including accelerated atherosclerosis in some workers. What phenomena have been posited as surrogate markers for the absorption of a medically important dose of carbon disulfide?

View full post for answer.

Question of the Day – Friday July 21, 2017

Question: Eculizumab (Soliris) is licensed in the United States for treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; both are rare, life-threatening illnesses. An increased risk for which infectious disease is associated with the use of Eculizumab?

View full post for answer.